Kenneth Research recently added a report on ‘Antiretroviral Drugs Market’ in its database of market research reports which provides its readers an in-depth analysis on the latest trends, growth opportunities and growth drivers that are associated with the growth of the market. The report additionally shares critical insights on the COVID-19 impacts on the Antiretroviral Drugs Market, along with the compound growth rate (CAGR) of the market for a projected period between 2022 and 2031. The report also includes analysis of the market by utilizing different analytical tools, such as PESTEL analysis and Porter’s five forces analysis. These tools also provide an in-depth analysis on the micro and macro-environmental factors that are associated with the growth of the market during the forecast period.
U.S. Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analsysis and U.S. Census Bureau mentions the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) avergae exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilest imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Antiretroviral Drugs Market products.
Download Sample of This Strategic Report: https://www.kennethresearch.com/sample-request-10086135
According to the statistics by the World Bank, the current health expenditure (% of GDP) around the world increased from 9.08% in 2001 to 9.84% in 2018. Additionally, the current health expenditure per capita (current US$) increased from USD 492.99 in 2001 to USD 1110.84 in 2018. Moreover, growing concern for deaths caused due to various diseases and the need for treatment that can lower the crude death rate, which in the year 2019 recorded close to 7% (per 1000 people), are also anticipated to drive the market growth during the forecast period.
According to Azoth Analytics research report “Global Antiretroviral Market: Analysis By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others), By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa), Drug Forecast (2019 Edition): Forecast to 2023”, the antiretroviral market is projected to display a robust growth represented by a CAGR of 4.70% during 2018 – 2023.
Over the recent years, Antiretroviral drugs market has been witnessing growth on account of several driving factors including growing prevalence of HIV AIDS, growing antiretroviral treatment coverage rate, and increase in availability of novel drugs with better efficacy. Moreover, factors such as growing medical spending, favorable steps by government of various countries, decreased cost of treatment, improved diagnosis rate, and rise in the favorable programs to provide diagnosis and treatment facilities to the unmet patient population has been driving the market growth of antiretroviral drugs. In addition, increasing uptake of INSTI based regimens, increasing awareness regarding HIV care and treatment procedures, new drug launches, and improved R&D pipeline are anticipated to fuel the market growth in forecasted period. However, growing portfolio of generic antiretroviral drugs is expected impact the overall market growth.
In this research report, the market is segmented on the basis of drug type. By drug type, the multi-class drug combinations are predicted to hold their dominant position in the market, especially Gilead Sciences product Biktarvy and ViiV Healthcare product Triumeq are expected to give more traction to the market. Amongst the regions, North America accounts for the largest regional share in the global antiretroviral market in 2017. The largest share of North America is attributed to high ART coverage rate and more emphasis towards prescribed branded drugs.
The report titled “Global Antiretroviral Market: Analysis By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others), By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa), Drug Forecast (2019 Edition): Forecast to 2023” has covered and analysed the potential of antiretroviral drugs market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the antiretroviral market. Additionally, the report also highlights market entry strategies for various companies across the globe along with drug sales forecast analysis.
Scope of the Report
Global Antiretroviral Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Antiretroviral Drugs Market– Size, Growth, Forecast
• Analysis By Drug Type – Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others.
• Drug Sales Forecast:
o Multi-Class Drugs Combination: Juluca®, Triumeq®, Genvoya®, Odefsey®, Stribild®, Biktarvy®.
o Nucleoside Reverse Transcriptase Inhibitors: Epzicom®/ Kivexa®.
o Non-Nucleoside Reverse Transcriptase Inhibitors: Edurant®.
o Protease Inhibitors: PREZISTA ® /PREZCOBIX® /REZOLSTA ®.
o Integrase Strand Transfer Inhibitors: Tivicay®, Isentress/Isentress HD®.
o CCR5 Inhibitor: Selzentry®/ Celsentri®.
Regional Antiretroviral Drugs Market – North America, Europe, Asia Pacific, Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Antiretroviral Drugs Market– Size, Growth, Forecast
• Analysis By Drug Type – Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others.
Country Analysis – U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Antiretroviral Drugs Market– Size, Growth, Forecast
• Analysis By Drug Type – Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others.
The Final Report will cover the impact analysis of COVID-19 on this industry:
Download Free Sample Reports Here – https://www.kennethresearch.com/sample-request-10086135
Other Report Highlights
• Product Sales Forecast.
• Market Dynamics – Drivers and Restraints.
• Market Trends.
• Porter Five Forces Analysis.
• SWOT Analysis.
• Company Analysis – Gilead Sciences Inc., ViiV Healthcare, Bristol-Myers Squibb, AbbVie Inc., Boehringer Ingelheim, Johnson & Johnson, Merck & Co., Cipla, Mylan.
Customization of the Report
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
About Us
Kenneth Research provides scheduled syndicated reports that help industry professionals and organizations decipher market trends to take significant decisions and plan strategies. We cater to a wide range of industries including healthcare & pharmaceuticals, ICT & telecom, automotive & transportation, energy & power, chemicals, FMCG & food, aerospace & defense, among others. Our research team ensures to track and analyze the industry on a regular basis to offer strategic business consultancy services on a global level. We, at Kenneth Research, are adept at capturing descriptive insights on crucial topics to help our clients make their informed decisions.
Contact Us
Name: Kenneth research
Email:sales@kennethresearch.com
Phone: +1 313 462 0609